Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nefita
- Development stage
- Unknown
- Lead developer
- Steadfast Medishield
- Modality
- Small Molecules
- Administration
- Oral, Parenteral
01
Overview
**Nefita** is a Steadfast renal-nutrition multivitamin brand intended to replenish water-soluble vitamins in people with kidney disease, including patients undergoing dialysis. The tablet formulation contains ascorbic acid, niacinamide, pyridoxine, folic acid, pantothenic acid, riboflavin, thiamine, methylcobalamin, and biotin; it is marketed for vitamin replacement where intake is inadequate or vitamin losses are excessive, including chronic renal failure and uremia. Steadfast also markets a Nefita injection with a different fixed combination of methylcobalamin, folic acid, niacinamide, and pyridoxine for post-dialysis nutritional support and anemia-related use. The Nefita name therefore covers more than one dosage form and composition.
- Brand names
- Nefita
Beyond the preview
Go deeper on Nefita.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nefita.